News articles about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive on Saturday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.3064918512985 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of equities analysts have weighed in on FATE shares. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Tuesday, January 9th. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Piper Jaffray reiterated a “top pick” rating and issued a $20.00 price target on shares of Fate Therapeutics in a research report on Tuesday, March 6th. Wedbush reiterated an “outperform” rating and issued a $10.00 price target (down from $19.00) on shares of Fate Therapeutics in a research report on Tuesday, March 6th. Finally, BidaskClub upgraded shares of Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Fate Therapeutics presently has an average rating of “Buy” and an average price target of $15.00.

Shares of NASDAQ:FATE opened at $11.21 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $14.45. The firm has a market cap of $603.18, a P/E ratio of -10.99 and a beta of 1.74.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts anticipate that Fate Therapeutics will post -0.94 earnings per share for the current year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.